Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1/2 Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02760485 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02760485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02760485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1/2 Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
December 29, 2016
Completion date
June 6, 2022
Enrollment
33 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma